WilmerHale Advises Karyopharm in $165M Private Placement

WilmerHale Advises Karyopharm in $165M Private Placement

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On December 5, 2022, Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that it entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $165 million before deducting any offering related expenses. Karyopharm agreed to sell 31,791,908 shares of common stock at a price of $5.19 per share and to issue accompanying warrants to purchase 9,537,563 shares of common stock at an exercise price of $6.36 per share. The private placement was led by Avidity Partners with participation by existing and new investors including Adage Capital Partners LP, Armistice Capital, HealthCor Management LP, Heights Capital Management, Marshall Wace, Rubric Capital Management LP, SilverArc Capital and Surveyor Capital (a Citadel company).

The WilmerHale team advising Karyopharm included Jason Kropp, Craig Hilts, Rebecca Chang, Alex Bloom and Aric Jain. 

 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel